⚠️ Research Use Only. This post is educational and does not constitute medical advice. All peptides discussed are sold for research purposes only. See our full disclaimer.
Overview
KPV is a tripeptide fragment of alpha-MSH studied for anti-inflammatory effects, particularly in gut and skin research.
What is KPV?
KPV is a remarkably simple tripeptide — just lysine, proline, and valine — that represents the C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH). Despite its small size, it retains most of α-MSH's anti-inflammatory activity without the pigmentation effects.
The peptide's primary research interest is in inflammatory bowel disease. KPV has been shown in animal models to reduce colitis severity, downregulate NF-κB inflammatory signaling, and decrease production of pro-inflammatory cytokines like TNF-α and IL-1β. Several papers have examined its potential for oral delivery in IBD, taking advantage of its stability against gastric digestion.
KPV is often paired with BPC-157 in gut research stacks. The combination is appealing because the two peptides work through different mechanisms — BPC-157 promotes tissue repair and angiogenesis while KPV directly suppresses inflammation. There is no head-to-head clinical trial of this combination, so the pairing remains research community practice rather than evidence-backed protocol.
KPV's research base is small. Most published work consists of animal studies and in vitro experiments, with limited human data. The peptide's safety profile in available research is excellent — its small size and lack of receptor-specific activity means few off-target effects have been reported.
Top Research Uses
- Gut inflammation research
- Skin inflammation
- IBD research
- Wound healing
- Oral mucosa research
Mechanism of Action
Anti-inflammatory peptide that suppresses NF-κB signaling and reduces pro-inflammatory cytokine production
Research Parameters
| Half-Life | Short, minutes in plasma |
| Typical Research Dose | Research protocols cite 200-500 mcg oral or subq |
| Administration Route | Oral, subcutaneous, topical |
| Reported Side Effects | Very few reported; well-tolerated profile in published research |
Dosing ranges cited from published research literature. These are not recommendations for human use. KPV is a research compound — not for human consumption.
Research Strength: Low-Moderate
KPV has a small but growing body of research. Most evidence is preclinical with limited human data.
Vendor & Sourcing Notes
Often sold in combination with BPC-157 for gut research applications
Always request third-party HPLC purity reports and mass spectrometry verification when sourcing research peptides. Quality varies significantly between suppliers.
Research Use Only — Compliance Notice
The information on this page is intended for educational and informational purposes only. KPV (Lysine-Proline-Valine (α-MSH 11-13)) is a research compound sold for laboratory research purposes only. It has not been approved by the FDA for human use. Nothing on this page constitutes medical advice or is intended to diagnose, treat, cure, or prevent any disease. Statements have not been evaluated by the FDA. Consult a qualified healthcare professional before considering any peptide-related protocols.
